Cargando…

Contribution of capecitabine for therapy of patients with gastroesophageal cancer: an update of recent phase III results

BACKGROUND: Capecitabine, an orally administered fluoropyrimidines, is widely used in the treatment of multiple malignancies. It has been extensively evaluated in patients with gastroesophageal carcinoma. Since recent reviews have discussed phase I/II trials (Cancer 107:221–231, 2006; Drugs 67:601–6...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cen, Putao, Tetzlaff, Eric D, Ajani, Jaffer A
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2008
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2503649/ https://www.ncbi.nlm.nih.gov/pubmed/18728703

Ejemplares similares

Customization of therapy for gastroesophageal adenocarcinoma patients
por: Mizrak Kaya, Dilsa, et al.
Publicado: (2018)

Treatment of localized gastric and gastroesophageal adenocarcinoma: the role of accurate staging and preoperative therapy
por: Badgwell, Brian, et al.
Publicado: (2017)

A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma
por: Burge, M E, et al.
Publicado: (2006)

Therapeutic Advances in the Treatment of Gastroesophageal Cancers
por: Li, Jenny J., et al.
Publicado: (2023)

Review of docetaxel in the treatment of gastric cancer
por: Tetzlaff, Eric D, et al.
Publicado: (2008)

Independent Stage Classification for Gastroesophageal Junction Adenocarcinoma
por: Hirata, Yuki, et al.
Publicado: (2023)

Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)
por: Shen, Lin, et al.
Publicado: (2014)

Recent advances in the management of gastric adenocarcinoma patients
por: Rogers, Jane E, et al.
Publicado: (2023)

Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study
por: Jiang, Haiping, et al.
Publicado: (2022)

Interim analysis of postoperative chemoradiotherapy with capecitabine and oxaliplatin versus capecitabine alone for pathological stage II and III rectal cancer: a randomized multicenter phase III trial
por: Feng, Yan-Ru, et al.
Publicado: (2016)

Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer
por: Saura, Cristina, et al.
Publicado: (2021)

A randomized phase II trial comparing capecitabine with oxaliplatin or docetaxel as first-line treatment in advanced gastric and gastroesophageal adenocarcinomas
por: Ni, Lu, et al.
Publicado: (2021)

Recent trend in gastric cancer treatment in the USA
por: Harada, Kazuto, et al.
Publicado: (2018)

A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study
por: Harbeck, Nadia, et al.
Publicado: (2016)

Recent advances in preoperative management of esophageal adenocarcinoma
por: Harada, Kazuto, et al.
Publicado: (2017)

Treatment Patterns for Gastroesophageal Junction Adenocarcinoma in the United States †
por: Kim, Bradford J., et al.
Publicado: (2020)

Gastroesophageal reflux in children: an updated review
por: Leung, Alexander KC, et al.
Publicado: (2019)

Trimodality treatment in gastric and gastroesophageal junction cancers: Current approach and future perspectives
por: Charalampakis, Nikolaos, et al.
Publicado: (2022)

Recent advances in the management of gastric adenocarcinoma patients
por: Harada, Kazuto, et al.
Publicado: (2018)

KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma
por: Tabernero, Josep, et al.
Publicado: (2021)

Postoperative Chemoradiotherapy With Capecitabine and Oxaliplatin vs Capecitabine for Stage II to III Rectal Cancer: A Randomized Clinical Trial
por: Li, Ning, et al.
Publicado: (2021)

Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial
por: Tang, Zhaoqing, et al.
Publicado: (2022)

Recent advances in treating oesophageal cancer
por: Harada, Kazuto, et al.
Publicado: (2020)

Phase III randomised trial comparing 6 vs. 12-month of capecitabine as adjuvant chemotherapy for patients with stage III colon cancer: final results of the JFMC37-0801 study
por: Tomita, Naohiro, et al.
Publicado: (2019)

The Role of CD44 in the Pathogenesis, Diagnosis, and Therapy of Gastric Cancer
por: Jang, Byung Ik, et al.
Publicado: (2011)

Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
por: Shah, Manish A., et al.
Publicado: (2023)

A Randomized Phase III Study of Patients With Advanced Gastric Adenocarcinoma Without Progression After Six Cycles of XELOX (Capecitabine Plus Oxaliplatin) Followed by Capecitabine Maintenance or Clinical Observation
por: Lee, Guk Jin, et al.
Publicado: (2023)

Treatment of advanced pancreatic neuroendocrine tumors: potential role of everolimus
por: Cen, Putao, et al.
Publicado: (2012)

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
por: Saura, Cristina, et al.
Publicado: (2020)

Recent progress of chemotherapy and biomarkers for gastroesophageal cancer
por: Maeda, Osamu, et al.
Publicado: (2019)

Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)
por: Boku, N, et al.
Publicado: (2019)

Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial
por: Jiang, Haiping, et al.
Publicado: (2020)

Refractory Gastroesophageal Reflux Disease: A Management Update
por: Rettura, Francesco, et al.
Publicado: (2021)

Prostate cancer and hypofractionation: reflections on recent randomised phase III clinical trial results
por: Dearnaley, David, et al.
Publicado: (2017)

S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial
por: Kim, Seung Tae, et al.
Publicado: (2014)

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
por: Barrios, Carlos H., et al.
Publicado: (2010)

Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: results of an extended multicentre phase-I trial
por: Hofheinz, R-D, et al.
Publicado: (2004)

Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer
por: Eggington, S, et al.
Publicado: (2006)

Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01)
por: Park, In Hae, et al.
Publicado: (2019)

Can We Understand the Clinical Biology of Gastric Cancer and Exploit it? May be, but It is a Challenge!
por: Ajani, Jaffer A.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_j7omoc36f1hc6mfq2g4d9omvdt